Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16496338rdf:typepubmed:Citationlld:pubmed
pubmed-article:16496338lifeskim:mentionsumls-concept:C0001792lld:lifeskim
pubmed-article:16496338lifeskim:mentionsumls-concept:C0332307lld:lifeskim
pubmed-article:16496338lifeskim:mentionsumls-concept:C0241910lld:lifeskim
pubmed-article:16496338lifeskim:mentionsumls-concept:C0085415lld:lifeskim
pubmed-article:16496338lifeskim:mentionsumls-concept:C0031437lld:lifeskim
pubmed-article:16496338lifeskim:mentionsumls-concept:C0205210lld:lifeskim
pubmed-article:16496338pubmed:issue3lld:pubmed
pubmed-article:16496338pubmed:dateCreated2006-4-3lld:pubmed
pubmed-article:16496338pubmed:abstractTextAutoimmune hepatitis is classically a disease of young women. Our aims were to determine its occurrence, clinical phenotype, and outcome in elderly patients and contrast findings to young adults. Two-hundred-and-five white North American adults with definite type 1 autoimmune hepatitis were grouped according to age at presentation and the groups compared. Forty-seven patients (23%) were aged > or = 60 years (median age, 68 years), and 31 patients (15%) were aged < or = 30 years (median age, 25 years). The patients > or = 60 years had a higher frequency of cirrhosis at presentation than the patients < or = 30 years (33% versus 10%, P = .03). They also had thyroid or rheumatic diseases more commonly (42% vs. 13%, P = .006). HLA DR3 occurred more frequently in the patients < or = 30 years than in those > or = 60 years (58% vs. 23%, P = .004), and HLA DR4 occurred more often in the patients > or = 60 years (47% vs. 13%, P = .003). Patients aged > or = 60 years failed corticosteroid treatment less commonly than those aged < or = 30 years (5% vs. 24%, P = .03). Autoimmune hepatitis occurred in patients aged 18-30 years (15%), 31-39 years (15%), 40-49 years (21%), 50-59 years (25%), and > or = 60 years (23%). Differences in age distribution, HLA frequencies, and treatment outcome occurred after age > or = 40 years. In conclusion, elderly patients have a greater frequency of cirrhosis at presentation and HLA DR4 than patients < or = 30 years, and they have a lower occurrence of treatment failure. Transitions in clinical and genetic phenotypes occur after age > or = 40 years. Genetic susceptibilities may favor etiologic factors that are age-related.lld:pubmed
pubmed-article:16496338pubmed:languageenglld:pubmed
pubmed-article:16496338pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16496338pubmed:citationSubsetIMlld:pubmed
pubmed-article:16496338pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16496338pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16496338pubmed:statusMEDLINElld:pubmed
pubmed-article:16496338pubmed:monthMarlld:pubmed
pubmed-article:16496338pubmed:issn0270-9139lld:pubmed
pubmed-article:16496338pubmed:authorpubmed-author:CzajaAlbert...lld:pubmed
pubmed-article:16496338pubmed:authorpubmed-author:CarpenterHers...lld:pubmed
pubmed-article:16496338pubmed:issnTypePrintlld:pubmed
pubmed-article:16496338pubmed:volume43lld:pubmed
pubmed-article:16496338pubmed:ownerNLMlld:pubmed
pubmed-article:16496338pubmed:authorsCompleteYlld:pubmed
pubmed-article:16496338pubmed:pagination532-8lld:pubmed
pubmed-article:16496338pubmed:meshHeadingpubmed-meshheading:16496338...lld:pubmed
pubmed-article:16496338pubmed:meshHeadingpubmed-meshheading:16496338...lld:pubmed
pubmed-article:16496338pubmed:meshHeadingpubmed-meshheading:16496338...lld:pubmed
pubmed-article:16496338pubmed:meshHeadingpubmed-meshheading:16496338...lld:pubmed
pubmed-article:16496338pubmed:meshHeadingpubmed-meshheading:16496338...lld:pubmed
pubmed-article:16496338pubmed:meshHeadingpubmed-meshheading:16496338...lld:pubmed
pubmed-article:16496338pubmed:meshHeadingpubmed-meshheading:16496338...lld:pubmed
pubmed-article:16496338pubmed:meshHeadingpubmed-meshheading:16496338...lld:pubmed
pubmed-article:16496338pubmed:meshHeadingpubmed-meshheading:16496338...lld:pubmed
pubmed-article:16496338pubmed:meshHeadingpubmed-meshheading:16496338...lld:pubmed
pubmed-article:16496338pubmed:meshHeadingpubmed-meshheading:16496338...lld:pubmed
pubmed-article:16496338pubmed:meshHeadingpubmed-meshheading:16496338...lld:pubmed
pubmed-article:16496338pubmed:meshHeadingpubmed-meshheading:16496338...lld:pubmed
pubmed-article:16496338pubmed:meshHeadingpubmed-meshheading:16496338...lld:pubmed
pubmed-article:16496338pubmed:meshHeadingpubmed-meshheading:16496338...lld:pubmed
pubmed-article:16496338pubmed:meshHeadingpubmed-meshheading:16496338...lld:pubmed
pubmed-article:16496338pubmed:meshHeadingpubmed-meshheading:16496338...lld:pubmed
pubmed-article:16496338pubmed:meshHeadingpubmed-meshheading:16496338...lld:pubmed
pubmed-article:16496338pubmed:year2006lld:pubmed
pubmed-article:16496338pubmed:articleTitleDistinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly.lld:pubmed
pubmed-article:16496338pubmed:affiliationDivision of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA. czaja.albert@mayo.edulld:pubmed
pubmed-article:16496338pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16496338lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16496338lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16496338lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16496338lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16496338lld:pubmed